
Researchers created a mini “liver-on-a-chip.” Tiny clusters of liver cells (shown in magenta) are embedded within a network of blood vessels (green). The vessels can carry fluid, shown here with blue dye, allowing scientists to study how liver disease develops.
Image Credit: Erin Tevonian and Ellen Kan
(CC BY-NC-ND 4.0)
Scientific Frontline: "At a Glance" Summary
- Main Discovery: Development of two advanced microfluidic liver tissue models that accurately replicate human liver architecture, including functional blood vessel networks and immune system interactions, to study metabolic diseases.
- Methodology: Researchers modified the "LiverChip" scaffold to support vascular growth and monocyte infiltration, while separately triggering disease states by exposing tissues to elevated levels of glucose, fatty acids, and insulin to mimic metabolic dysfunction.
- Key Data: The study highlighted that metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 100 million Americans; the model demonstrated that the drug resmetirom can induce inflammation, potentially explaining its limited 30% patient efficacy.
- Significance: These platforms provide the first reliable method to observe the interplay between hepatocytes, immune cells, and vasculature in a lab setting, offering a superior alternative to animal models for predicting human drug responses.
- Future Application: Accelerating the identification and safety testing of therapeutics for fatty liver disease (MASLD) and its severe form (MASH), as well as facilitating patient-specific drug screening.
- Branch of Science: Tissue Engineering and Biomedical Engineering.
- Additional Detail: The research confirmed that insulin resistance directly leads to vascular leakiness and increased inflammation markers, key drivers in the progression from early-stage liver disease to fibrosis.




.jpg)
.jpg)
.jpg)

.jpg)

.jpg)

.jpg)
